Will neratinib/neratinib be included in medical insurance in 2024?

Neratinib is used alone or with other drugs to treat early-stage HER2-positive breast cancer. It is also used to treat HER2-positive breast cancer that is advanced or has spread to other parts of the body (metastatic). Neratinib can be used in breast cancer only if a patient's tumor tests positive for a protein called human epidermal growth factor receptor 2 (HER2). The HER2 protein can accelerate the growth of cancer cells. Neratinib may also be used after patients are receiving certain other cancer drugs and for purposes not listed in this Medication Guide.

Neratinib works by targeting and blockingEGFR and its kinases. In some cancers, these receptors are overactive, causing cells to grow and divide too quickly. By blocking the work of these special enzymes, this drug slows the growth of cancer cells. The original drug of neratinib has been launched in China, and has entered the scope of Class B medical insurance reimbursement through the relevant regulations of the National Medical Insurance Administration. The reimbursement conditions are limited to adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer who receive intensive adjuvant therapy after receiving trastuzumab-containing adjuvant therapy. Eligible patients in China can purchase the drug at hospitals or pharmacies that accept medical insurance reimbursement, but patients who do not meet the conditions can only purchase the drug at their own expense. SpecificationsThe price of each box of 40mg*180 tablets may be around 7,000 yuan.

In general, neratinib, as an important drug for the treatment of HER-positive breast cancer, has been widely used and recognized at home and abroad. For eligible patients, the medical insurance reimbursement policy has brought them substantial financial support.